IL97932A - Proteins and polypeptides having substituted cysteine residues and pharmaceutical compositions containing the same - Google Patents
Proteins and polypeptides having substituted cysteine residues and pharmaceutical compositions containing the sameInfo
- Publication number
- IL97932A IL97932A IL97932A IL9793291A IL97932A IL 97932 A IL97932 A IL 97932A IL 97932 A IL97932 A IL 97932A IL 9793291 A IL9793291 A IL 9793291A IL 97932 A IL97932 A IL 97932A
- Authority
- IL
- Israel
- Prior art keywords
- protein
- leu
- polypeptide
- integer
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51904790A | 1990-05-04 | 1990-05-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL97932A0 IL97932A0 (en) | 1992-06-21 |
| IL97932A true IL97932A (en) | 1998-02-22 |
Family
ID=24066559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL97932A IL97932A (en) | 1990-05-04 | 1991-04-24 | Proteins and polypeptides having substituted cysteine residues and pharmaceutical compositions containing the same |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0458064B1 (da) |
| JP (1) | JPH069696A (da) |
| KR (1) | KR100213455B1 (da) |
| AT (1) | ATE163431T1 (da) |
| AU (1) | AU639324B2 (da) |
| CA (1) | CA2041742A1 (da) |
| DE (1) | DE69128944T2 (da) |
| DK (1) | DK0458064T3 (da) |
| ES (1) | ES2113354T3 (da) |
| FI (1) | FI912144L (da) |
| GR (1) | GR3026436T3 (da) |
| IE (1) | IE911511A1 (da) |
| IL (1) | IL97932A (da) |
| NO (1) | NO911752L (da) |
| NZ (1) | NZ237959A (da) |
| PT (1) | PT97539B (da) |
| ZA (1) | ZA913359B (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| GB9100381D0 (en) * | 1991-01-09 | 1991-02-20 | Erba Carlo Spa | Human bfgf derivatives,their analogs and process for their production |
| AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
| US5336488A (en) * | 1991-08-07 | 1994-08-09 | American Cyanamid Company | Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines |
| EP0618927A4 (en) * | 1991-12-10 | 1995-05-24 | Tanox Biosystems Inc | CYTOKINE WITH AN UNPAIRED CYSTEIN REST AND CONJUGATES OF IT. |
| JPH08506095A (ja) * | 1992-11-25 | 1996-07-02 | アムジェン ボールダー インコーポレイテッド | 改変インシュリン様成長因子 |
| EP0622394A1 (en) * | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use |
| IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| AU2008202371B2 (en) * | 1999-01-14 | 2012-08-02 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| CN1318443C (zh) | 2000-05-16 | 2007-05-30 | 博尔德生物技术公司 | 含游离半胱氨酸残基的蛋白重折叠的方法 |
| WO2002055532A2 (en) * | 2001-01-11 | 2002-07-18 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
| HRP20040448A2 (en) * | 2001-11-20 | 2006-02-28 | Pharmacia Corporation | Method for detecting cells with numerical chromosomal abnormalities |
| RS20050502A (sr) | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću |
| EP1673464A2 (en) * | 2003-10-10 | 2006-06-28 | Novo Nordisk A/S | Conjugation of peptides |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| WO2007041614A2 (en) | 2005-10-03 | 2007-04-12 | Bolder Biotechnology, Inc. | Long acting vegf inhibitors and methods of use |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| CN118767117A (zh) | 2010-01-22 | 2024-10-15 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
| US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| ATE198353T1 (de) * | 1988-08-24 | 2001-01-15 | American Cyanamid Co | Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
-
1991
- 1991-04-18 ES ES91106224T patent/ES2113354T3/es not_active Expired - Lifetime
- 1991-04-18 DE DE69128944T patent/DE69128944T2/de not_active Expired - Fee Related
- 1991-04-18 AT AT91106224T patent/ATE163431T1/de not_active IP Right Cessation
- 1991-04-18 EP EP91106224A patent/EP0458064B1/en not_active Expired - Lifetime
- 1991-04-18 DK DK91106224.8T patent/DK0458064T3/da active
- 1991-04-24 IL IL97932A patent/IL97932A/en not_active IP Right Cessation
- 1991-04-26 NZ NZ237959A patent/NZ237959A/en unknown
- 1991-04-29 AU AU76075/91A patent/AU639324B2/en not_active Ceased
- 1991-05-02 PT PT97539A patent/PT97539B/pt not_active IP Right Cessation
- 1991-05-02 JP JP3128190A patent/JPH069696A/ja active Pending
- 1991-05-02 CA CA002041742A patent/CA2041742A1/en not_active Abandoned
- 1991-05-03 NO NO91911752A patent/NO911752L/no unknown
- 1991-05-03 IE IE151191A patent/IE911511A1/en not_active Application Discontinuation
- 1991-05-03 ZA ZA913359A patent/ZA913359B/xx unknown
- 1991-05-03 FI FI912144A patent/FI912144L/fi not_active Application Discontinuation
- 1991-05-03 KR KR1019910007216A patent/KR100213455B1/ko not_active Expired - Fee Related
-
1998
- 1998-03-24 GR GR970403459T patent/GR3026436T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL97932A0 (en) | 1992-06-21 |
| EP0458064A3 (en) | 1992-06-17 |
| KR910020032A (ko) | 1991-12-19 |
| ES2113354T3 (es) | 1998-05-01 |
| DE69128944T2 (de) | 1998-06-25 |
| PT97539A (pt) | 1992-02-28 |
| NO911752L (no) | 1991-11-05 |
| GR3026436T3 (en) | 1998-06-30 |
| AU639324B2 (en) | 1993-07-22 |
| FI912144A0 (fi) | 1991-05-03 |
| DE69128944D1 (de) | 1998-04-02 |
| CA2041742A1 (en) | 1991-11-05 |
| JPH069696A (ja) | 1994-01-18 |
| PT97539B (pt) | 1998-08-31 |
| NZ237959A (en) | 1994-05-26 |
| FI912144A7 (fi) | 1991-11-05 |
| EP0458064B1 (en) | 1998-02-25 |
| KR100213455B1 (ko) | 1999-08-02 |
| FI912144L (fi) | 1991-11-05 |
| AU7607591A (en) | 1991-11-07 |
| EP0458064A2 (en) | 1991-11-27 |
| DK0458064T3 (da) | 1998-04-27 |
| ATE163431T1 (de) | 1998-03-15 |
| NO911752D0 (no) | 1991-05-03 |
| IE911511A1 (en) | 1991-11-06 |
| ZA913359B (en) | 1992-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0458064B1 (en) | Stabilization of somatotropins by modification of cysteine residues | |
| US5951972A (en) | Stabilization of somatotropins and other proteins by modification of cysteine residues | |
| EP0355460B1 (en) | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization | |
| JP5431874B2 (ja) | ポリエチレングリコール−grf結合体の部位特異的調製方法 | |
| AU714439B2 (en) | Amylin agonist peptides and uses therefor | |
| IL97232A (en) | Polypropylene polymer flame retardants and a process for their preparation | |
| JP2003525864A (ja) | 共有結合で架橋されたインスリンダイマー | |
| JP2002528562A (ja) | 長さのばらつきが小さいポリアミド連鎖、その連鎖の製造方法およびその連鎖とタンパク質の複合体 | |
| CA1268898A (en) | Growth hormone-releasing peptides and method of treating mammals therewith | |
| IE60870B1 (en) | Tripeptides and pharmaceutical compositions containing them | |
| EP1179537B1 (en) | Solid phase peptide synthesis method | |
| CA2507616A1 (en) | Highly stable pacap/vip-derived peptides | |
| JPH09502175A (ja) | 免疫およびcns療法に有用な新規トリペプチド | |
| KR20080041661A (ko) | 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬 | |
| JPH05279388A (ja) | 超活性grf類縁体 | |
| US20060134736A1 (en) | Human growth hormone conjugated with biocompatible polymer | |
| KR0130969B1 (ko) | 동물의 재조합 소마토트로핀과 그의 응집을 막는 방법 및 그를 포함하는 제약학적 조성물 | |
| JPS6330499A (ja) | オピオイドペプチド・ポリペプチド複合体 | |
| Pató et al. | Synthesis of New Poly (N-Vinyl Pyrrolidone-Co-Maleic Acid) Peptide Hormone Conjugates with Anticancer Activity | |
| HU201566B (en) | Process for producing new analoguse of activatin factor of human growth hormon and pharmaceutical and veterinair compositions containing them | |
| JPWO1999057147A1 (ja) | ヒトトロンボポエチン変異体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |